Loading clinical trials...
Loading clinical trials...
A Three-way Incomplete Block Crossover Study to Investigate the 24-hour Pulmonary Function of Three Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder vs. Placebo, in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Interventions
Fluticasone Furoate (FF)/GW642444 Inhalation Powder
placebo
Locations
8
United States
GSK Investigational Site
DeLand, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Madisonville, Kentucky, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Greenville, South Carolina, United States
GSK Investigational Site
Orangeburg, South Carolina, United States
Start Date
January 1, 2010
Primary Completion Date
July 1, 2010
Completion Date
July 1, 2010
Last Updated
November 9, 2017
NCT06831994
NCT02755974
NCT05050591
NCT05913765
NCT05592847
NCT00683722
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions